Category: Press Release - Part 2

PRINCETON, NJ – June 8, 2006 Laureate Pharma, a partner company of Safeguard Scientifics (NYSE: SFE), today announced plans to invest up to $9 million to expand its biopharmaceutical manufacturing facility in Princeton, NJ. The facility expansion will provide Laureate Pharma with a new pilot production plant with two separate production suites, and expanded purification production capacity to support additional cGMP production. The new pilot plant will include stainless steel…

PRINCETON, NJ – June 1, 2006 Laureate Pharma, a biopharmaceutical development and protein production company, is sponsoring a live webcast at 2PM EDT on June 8 on “Development Of A Third-Generation Antibody For Therapy Of Prostate Cancer.” The free webcast, presented by BioPharm International, will include presentations by experts from Cytogen Corporation, Laureate Pharma, and Memorial Sloan Kettering Cancer Center. The development of radiolabeled therapeutic antibodies is a sophisticated process…

PRINCETON, NJ AND ATLANTA, GA – May 10, 2006 Laureate Pharma, Inc., a full service biopharmaceutical development and protein production company, today announced that it has entered into a biopharmaceutical manufacturing agreement with Iconic Therapeutics, Inc. for cGMP manufacture of hI-con1, a “bi-functional immunoprotein”. Laureate’s services include cGMP protein production, purification and aseptic filling of hI-con1 for Iconic Therapeutics. Terms of the agreement were not disclosed. “Iconic Therapeutics has a…

Bothell, WA and Princeton, NJ – April 25, 2006 Seattle Genetics, Inc. (Nasdaq: SGEN) and Laureate Pharma, Inc. announced today that they have entered into an agreement for manufacturing of Seattle Genetics SGN-33 and SGN-70 humanized monoclonal antibody product candidates. Under the terms of the agreement, Laureate Pharma will perform scale-up and cGMP manufacturing of clinical trial materials for both programs. “These manufacturing campaigns are an important part of our…

LAUREATE PHARMA AND BRADMER PHARMACEUTICALS ANNOUNCE THEIR DEVELOPMENT AND MANUFACTURING AGREEMENT ON A THERAPEUTIC MONOCLONAL ANTIBODY PRODUCT FOR TREATMENT OF BRAIN CANCER Princeton, NJ – March 16, 2006 – Laureate Pharma, Inc. announced today that it has entered into a biopharmaceutical development and manufacturing agreement with Bradmer Pharmaceuticals Inc. for process development and cGMP manufacture of the monoclonal antibody precursor of Neuradiab, Bradmer’s anticipated multi-center clinical candidate for treatment of…

Laureate to Expand Its Bioprocessing Services at Princeton, NJ Facility Princeton, NJ – December 28, 2005 – Laureate Pharma, Inc., a provider of bioprocessing services to pharmaceutical and biopharmaceutical companies, announced today that it had agreed to sell its Totowa, NJ operations to Discovery Laboratories, Inc. (NASDAQ: DSCO) for $16.0 million in cash.  The transaction is expected to close shortly. Laureate Pharma is a wholly-owned subsidiary of Safeguard Scientifics, Inc….

PRINCETON, NJ – September 21, 2005 – Laureate Pharma, Inc. and Enobia Pharma, Inc. announced today that they have entered into a biopharmaceutical development and manufacturing agreement for process development and manufacture of cGMP batches of Enobia’s recombinant enzyme sPHEX Metallo Peptidase. The project is well underway and Laureate Pharma expects to supply Enobia with material for their Phase I clinical trials 3Q 2006. Terms of the agreement were not…

PRINCETON, N.J. and GIBBSTOWN, N.J., September 7th, 2005 — Laureate Pharma, Inc. announced the appointment of Michael J. Cavanaugh as Vice President of Sales, Marketing and Business Development. In this newly created position, Mr. Cavanaugh will be responsible for Laureate’s worldwide sales and marketing and business development activities supporting the company’s contract development, manufacturing and bioprocessing business. “We are delighted to welcome Michael to Laureate’s management team,” said Robert J….

PRINCETON, N.J. and GIBBSTOWN, N.J., March 3 /PRNewswire/ — Laureate Pharma, Inc. and EMD Chemicals Inc. announced today that they have entered into a strategic collaboration for the co-marketing and promotion of biopharmaceutical products and services. Under the agreement, EMD Chemicals will utilize its expertise in packing and testing large-scale ion exchange chromatography columns in combination with Laureate Pharma’s expertise in protein process development, production, and purification to further penetrate…

PRINCETON, N.J., Jan. 7, 2005 /PRNewswire/ — Laureate Pharma is pleased to announce that the company has been acquired by Safeguard Scientifics, Inc. (NYSE: SFE – News), a strategic growth partner for companies in the Time-to-Volume stage of development. Laureate Pharma will continue to serve its clients in the growing biopharmaceutical and pharmaceutical contract manufacturing services industry. (Logo: http://www.newscom.com/cgi-bin/prnh/20020723/LPHARMLOGO ) In addition to expansion capital, Safeguard Scientifics provides its companies…